You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDiethylstilbestrol
Accession NumberDB00255  (APRD00920, EXPT01164)
TypeSmall Molecule
GroupsApproved
DescriptionA synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed)
Structure
Thumb
Synonyms
(E)-3,4-bis(4-hydroxyphenyl)-3-hexene
(e)-4,4'-(1,2-Diethyl-1,2-ethenediyl)bisphenol
4,4'-Dihydroxy-alpha,beta-diethylstilbene
4,4'-dihydroxy-α,β-diethylstilbene
alpha,Alpha'-diethyl-(e)-4,4'-stilbenediol
DES
Diethylstilbestrol
Diethylstilbestrolum
Dietilestilbestrol
Distilbene
Stilboestrol
trans-4,4'-(1,2-diethyl-1,2-ethenediyl)bisphenol
trans-Diethylstilbesterol
trans-Diethylstilbestrol
trans-Diethylstilboesterol
α,α'-diethyl-(E)-4,4'-stilbenediol
External Identifiers
  • RCRA waste number U089
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Honvol Ampoules 250mgLiquid250 mgIntravenousCarter Horner Corp.1956-12-312000-11-17Canada
Honvol Tablets 100mgTablet100 mgOralCarter Horner Corp.1958-12-312001-05-22Canada
Stilbestrol 0.5mg TabletTablet.5 mgOralGlaxo Canada Inc1993-12-311998-07-30Canada
Stilbestrol 1.0mg TabletTablet1 mgOralGlaxo Canada Inc1991-12-311996-09-10Canada
Stilbestrol Tab 1mgTablet1 mgOralEverest Pharmaceuticals Ltd.1980-12-311999-07-14Canada
Stilbestrol Tablets 0.1 mgTablet0.105 mgOralWellspring Pharmaceutical Canada Corp1996-07-302009-02-23Canada
Stilbestrol Tablets 0.5 mgTablet0.51 mgOralWellspring Pharmaceutical Canada Corp1997-04-022009-02-23Canada
Stilbestrol Tablets 1.0 mgTablet1.0 mgOralWellspring Pharmaceutical Canada Corp1996-07-302009-02-23Canada
Stilboestrol Tab 0.1mgTablet.1 mgOralAllen & Hanburys A Glaxo Canada Ltd. Co.1951-12-311996-09-10Canada
Stilboestrol Tab 0.5mgTablet.5 mgOralAllen & Hanburys A Glaxo Canada Ltd. Co.1951-12-311996-09-20Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DistilbeneGerda
StilbestrolNysco
StilbetinBristol Myers-Squibb
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Diethylstilbestrol diphosphate
522-40-7
Thumb
  • InChI Key: NLORYLAYLIXTID-ISLYRVAYSA-N
  • Monoisotopic Mass: 428.078991664
  • Average Mass: 428.314
DBSALT001389
Diethylstilbestrol diphosphate sodium
ThumbNot applicableDBSALT001169
Categories
UNII731DCA35BT
CAS number56-53-1
WeightAverage: 268.3502
Monoisotopic: 268.146329884
Chemical FormulaC18H20O2
InChI KeyRGLYKWWBQGJZGM-ISLYRVAYSA-N
InChI
InChI=1S/C18H20O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,19-20H,3-4H2,1-2H3/b18-17+
IUPAC Name
4-[4-(4-hydroxyphenyl)hex-3-en-3-yl]phenol
SMILES
CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
Pharmacology
IndicationUsed in the treatment of prostate cancer. Previously used in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery.
Structured Indications Not Available
PharmacodynamicsDiethylstilbestrol is a synthetic estrogen that was developed to supplement a woman's natural estrogen production. In 1971, the Food and Drug Administration (FDA) issued a Drug Bulletin advising physicians to stop prescribing DES to pregnant women because it was linked to a rare vaginal cancer in female offspring.
Mechanism of actionEstrogens diffuse into their target cells and interact with a protein receptor, the estrogen receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. The effect of Estrogen binding their receptors causes downstream increases the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).
TargetKindPharmacological actionActionsOrganismUniProt ID
Estrogen receptorProteinyes
agonist
HumanP03372 details
Estrogen-related receptor gammaProteinyes
agonist
HumanP62508 details
Estrogen receptor betaProteinyes
agonist
HumanQ92731 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with 1,10-Phenanthroline.Experimental
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Diethylstilbestrol.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Diethylstilbestrol.Experimental, Illicit
3,4-DichloroisocoumarinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Diethylstilbestrol can be decreased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Diethylstilbestrol.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Diethylstilbestrol.Experimental, Illicit
AbciximabDiethylstilbestrol may decrease the anticoagulant activities of Abciximab.Approved
AcenocoumarolDiethylstilbestrol may decrease the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Diethylstilbestrol can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Diethylstilbestrol.Approved
AcitretinThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Acitretin.Approved
AdapaleneThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Adapalene.Approved
AfatinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Albendazole.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Diethylstilbestrol.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Diethylstilbestrol.Experimental
AlectinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Diethylstilbestrol can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Alitretinoin.Approved, Investigational
AlogliptinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Alpha-1-proteinase inhibitor.Approved
AmantadineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Amantadine.Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be increased when it is combined with Diethylstilbestrol.Experimental
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Diethylstilbestrol.Approved
Aminohippuric acidThe serum concentration of Diethylstilbestrol can be increased when it is combined with Aminohippuric acid.Approved
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Diethylstilbestrol.Approved
AmiodaroneThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Diethylstilbestrol.Approved
AmprenavirThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Amsacrine.Approved
AnastrozoleThe therapeutic efficacy of Anastrozole can be decreased when used in combination with Diethylstilbestrol.Approved, Investigational
AncrodDiethylstilbestrol may decrease the anticoagulant activities of Ancrod.Investigational
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Diethylstilbestrol.Investigational
Anthrax immune globulin humanDiethylstilbestrol may increase the thrombogenic activities of Anthrax immune globulin human.Approved
Antithrombin III humanThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Antithrombin III human.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Diethylstilbestrol.Investigational
ApixabanThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Apixaban.Approved
AprepitantThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Aprotinin.Approved, Withdrawn
ArdeparinDiethylstilbestrol may decrease the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Argatroban.Approved, Investigational
ArmodafinilThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Armodafinil.Approved, Investigational
ArtemetherThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Artemether.Approved
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Diethylstilbestrol resulting in a loss in efficacy.Approved
AstemizoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Diethylstilbestrol can be increased when it is combined with Atenolol.Approved
AtorvastatinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Azithromycin.Approved
BarbexacloneThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Barbexaclone.Experimental
BarbitalThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Barbital.Illicit
BatimastatThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Batimastat.Experimental
BecaplerminDiethylstilbestrol may decrease the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe serum concentration of Beclomethasone can be increased when it is combined with Diethylstilbestrol.Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
BenazeprilThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Benazepril.Approved, Investigational
BenzamidineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Benzamidine.Experimental
BenzocaineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Diethylstilbestrol can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Diethylstilbestrol.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Diethylstilbestrol.Approved, Investigational
BexaroteneThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Bexarotene.Approved, Investigational
BexaroteneThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Bexarotene.Approved, Investigational
Bi201335The serum concentration of Diethylstilbestrol can be decreased when it is combined with Bi201335.Investigational
BiperidenThe serum concentration of Diethylstilbestrol can be increased when it is combined with Biperiden.Approved
BivalirudinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Boceprevir.Approved
BosentanThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Bosutinib.Approved
BromocriptineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Bromocriptine.Approved, Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Diethylstilbestrol.Approved
BuprenorphineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Diethylstilbestrol can be increased when it is combined with Buspirone.Approved, Investigational
C1 Esterase Inhibitor (Human)Diethylstilbestrol may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).Approved
C1 Esterase Inhibitor (Recombinant)Diethylstilbestrol may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Diethylstilbestrol.Approved
CaffeineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Diethylstilbestrol can be increased when it is combined with Candesartan.Approved
CandoxatrilThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Captopril.Approved
CarbamazepineThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Carbamazepine.Approved, Investigational
CarvedilolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Diethylstilbestrol can be increased when it is combined with Caspofungin.Approved
CelecoxibCelecoxib may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
CertoparinDiethylstilbestrol may decrease the anticoagulant activities of Certoparin.Approved
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Diethylstilbestrol.Approved
ChloroquineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Diethylstilbestrol can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Diethylstilbestrol can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Cholesterol.Experimental
CholestyramineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Cholestyramine.Approved
Cholic AcidThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Cholic Acid.Approved
ChymostatinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Chymostatin.Experimental
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
CilastatinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Diethylstilbestrol can be increased when it is combined with Citalopram.Approved
Citric AcidDiethylstilbestrol may decrease the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Clarithromycin.Approved
ClobazamThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Clobazam.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Diethylstilbestrol.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Diethylstilbestrol.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Diethylstilbestrol.Approved
ClofazimineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Colchicine.Approved
ColesevelamThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Colestipol.Approved
ColforsinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Colforsin.Experimental
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Diethylstilbestrol.Approved
CrizotinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Diethylstilbestrol.Approved, Investigational
CyclosporineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Diethylstilbestrol can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dactinomycin.Approved
DalteparinDiethylstilbestrol may decrease the anticoagulant activities of Dalteparin.Approved
DanaparoidDiethylstilbestrol may decrease the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarunavirThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Daunorubicin.Approved
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Diethylstilbestrol.Investigational
DesipramineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Desipramine.Approved
DesirudinDiethylstilbestrol may decrease the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Diethylstilbestrol.Approved
DesloratadineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Diethylstilbestrol.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Diethylstilbestrol.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Diethylstilbestrol.Experimental, Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Diethylstilbestrol.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Diethylstilbestrol.Vet Approved
DextranDiethylstilbestrol may decrease the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Diethylstilbestrol may decrease the anticoagulant activities of Dextran 40.Approved
Dextran 70Diethylstilbestrol may decrease the anticoagulant activities of Dextran 70.Approved
Dextran 75Diethylstilbestrol may decrease the anticoagulant activities of Dextran 75.Approved
DextromethorphanThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Diethylstilbestrol can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicoumarolDiethylstilbestrol may decrease the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Diethylstilbestrol.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Diethylstilbestrol.Approved
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Diethylstilbestrol.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Diethylstilbestrol.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Diethylstilbestrol.Approved
DihydroergotamineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Diethylstilbestrol can be increased when it is combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Diethylstilbestrol.Approved, Investigational
DoxazosinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dronedarone.Approved
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Diethylstilbestrol.Approved
EcabetThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Ecabet.Approved, Investigational
Edetic AcidDiethylstilbestrol may decrease the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Edoxaban.Approved
ElafinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Elafin.Investigational
ElbasvirThe serum concentration of Diethylstilbestrol can be increased when it is combined with Elbasvir.Approved
ElvitegravirThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Elvitegravir.Approved
EnalaprilThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Enalkiren.Experimental
EnoxaparinDiethylstilbestrol may decrease the anticoagulant activities of Enoxaparin.Approved
EntacaponeThe metabolism of Diethylstilbestrol can be decreased when combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Diethylstilbestrol can be increased when it is combined with Enzalutamide.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Diethylstilbestrol.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Diethylstilbestrol.Approved
ErgonovineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstramustineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Diethylstilbestrol.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Diethylstilbestrol.Approved
Ethyl biscoumacetateDiethylstilbestrol may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational, Vet Approved
EtoposideThe serum concentration of Diethylstilbestrol can be increased when it is combined with Etoposide.Approved
EtoricoxibEtoricoxib may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
EtravirineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Etravirine.Approved
ExemestaneThe therapeutic efficacy of Exemestane can be decreased when used in combination with Diethylstilbestrol.Approved, Investigational
ExenatideThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Exenatide.Approved, Investigational
FelbamateThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Felbamate.Approved
FelodipineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fidaxomicin.Approved
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Diethylstilbestrol.Approved
fluasteroneThe serum concentration of fluasterone can be increased when it is combined with Diethylstilbestrol.Investigational
FluconazoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fluconazole.Approved
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Diethylstilbestrol.Approved
FluindioneDiethylstilbestrol may decrease the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Diethylstilbestrol.Approved, Vet Approved
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Diethylstilbestrol.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Diethylstilbestrol.Approved, Withdrawn
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Diethylstilbestrol.Approved
FluoxetineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Diethylstilbestrol.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Diethylstilbestrol.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Diethylstilbestrol.Approved
FlurazepamThe serum concentration of Diethylstilbestrol can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Diethylstilbestrol.Approved
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Diethylstilbestrol.Approved
FluvoxamineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FondaparinuxDiethylstilbestrol may decrease the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumDiethylstilbestrol may decrease the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Diethylstilbestrol.Approved, Investigational, Withdrawn
FosamprenavirThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Fosinopril.Approved
FosphenytoinThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Fosphenytoin.Approved
GabexateThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Gabexate.Investigational
GefitinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Gefitinib.Approved, Investigational
GeldanamycinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Geldanamycin.Experimental
GenisteinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Diethylstilbestrol can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Glycerol.Experimental
GM6001The serum concentration of Diethylstilbestrol can be decreased when it is combined with GM6001.Experimental
Gramicidin DThe serum concentration of Diethylstilbestrol can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Grepafloxacin.Withdrawn
GriseofulvinThe metabolism of Diethylstilbestrol can be increased when combined with Griseofulvin.Approved, Vet Approved
HaloperidolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Haloperidol.Approved
HE3286The serum concentration of HE3286 can be increased when it is combined with Diethylstilbestrol.Investigational
HeparinDiethylstilbestrol may decrease the anticoagulant activities of Heparin.Approved, Investigational
HexobarbitalThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Hexobarbital.Approved
HirulogThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Hirulog.Experimental
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Diethylstilbestrol.Approved, Investigational
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Diethylstilbestrol.Approved, Vet Approved
IdelalisibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Diethylstilbestrol can be decreased when it is combined with idraparinux.Investigational
ImatinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Imatinib.Approved
ImidaprilThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Imidapril.Investigational
ImipramineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Imipramine.Approved
IndinavirThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Indomethacin.Approved, Investigational
IsavuconazoniumThe serum concentration of Diethylstilbestrol can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Isoflurophate.Approved, Withdrawn
IsotretinoinThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Isotretinoin.Approved
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Diethylstilbestrol.Investigational
ItraconazoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ivermectin.Approved, Vet Approved
IxazomibThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Ixazomib.Approved
KetamineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ketoconazole.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Diethylstilbestrol.Approved, Investigational
LansoprazoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Lapatinib.Approved, Investigational
LenalidomideDiethylstilbestrol may increase the thrombogenic activities of Lenalidomide.Approved
LepirudinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Lepirudin.Approved
LevofloxacinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Linagliptin.Approved
LiothyronineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Diethylstilbestrol can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Diethylstilbestrol can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Diethylstilbestrol can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Lovastatin.Approved, Investigational
LumacaftorThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
MaprotilineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Maprotiline.Approved
ME-609The serum concentration of ME-609 can be increased when it is combined with Diethylstilbestrol.Investigational
MebendazoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Mebendazole.Approved, Vet Approved
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Diethylstilbestrol.Approved
MefloquineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Diethylstilbestrol can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Diethylstilbestrol.Vet Approved
MeprobamateThe serum concentration of Diethylstilbestrol can be increased when it is combined with Meprobamate.Approved, Illicit
MethadoneThe serum concentration of Diethylstilbestrol can be increased when it is combined with Methadone.Approved
MethohexitalThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Methohexital.Approved
MethylphenobarbitalThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Diethylstilbestrol.Approved, Vet Approved
MetoprololThe serum concentration of Diethylstilbestrol can be increased when it is combined with Metoprolol.Approved, Investigational
MetreleptinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Metreleptin.Approved
MibefradilThe serum concentration of Diethylstilbestrol can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Mifepristone.Approved, Investigational
MitomycinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Moexipril.Approved
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Diethylstilbestrol.Approved, Vet Approved
MorphineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Morphine.Approved, Investigational
Mycophenolic acidThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Mycophenolic acid.Approved
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabumetoneNabumetone may increase the thrombogenic activities of Diethylstilbestrol.Approved
NadroparinDiethylstilbestrol may decrease the anticoagulant activities of Nadroparin.Approved
NafamostatThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Nafamostat.Investigational
NafcillinThe metabolism of Diethylstilbestrol can be increased when combined with Nafcillin.Approved
NaltrexoneThe serum concentration of Diethylstilbestrol can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Diethylstilbestrol can be increased when it is combined with Naringenin.Experimental
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Diethylstilbestrol.Investigational
NCX 4016The serum concentration of Diethylstilbestrol can be decreased when it is combined with NCX 4016.Investigational
NefazodoneThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Neostigmine.Approved, Vet Approved
NevirapineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Nitroaspirin.Investigational
NorethisteroneThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Norethisterone.Approved
Oleoyl estroneThe serum concentration of Oleoyl estrone can be increased when it is combined with Diethylstilbestrol.Investigational
OmapatrilatThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Omapatrilat.Investigational
OmeprazoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OspemifeneThe risk or severity of adverse effects can be increased when Diethylstilbestrol is combined with Ospemifene.Approved
OtamixabanThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Diethylstilbestrol.Approved
OxcarbazepineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Oxcarbazepine.Approved
P-NitrophenolThe serum concentration of Diethylstilbestrol can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Diethylstilbestrol.Approved, Vet Approved
Palmitic AcidThe serum concentration of Diethylstilbestrol can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Pantoprazole.Approved
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Diethylstilbestrol.Approved
ParecoxibParecoxib may increase the thrombogenic activities of Diethylstilbestrol.Approved
ParoxetineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Diethylstilbestrol.Approved
PentobarbitalThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateDiethylstilbestrol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Perindopril.Approved
PhenindioneDiethylstilbestrol may decrease the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Phenobarbital.Approved
PhenprocoumonDiethylstilbestrol may decrease the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Phosphoramidon.Experimental
PimozideThe serum concentration of Diethylstilbestrol can be increased when it is combined with Pimozide.Approved
Platelet Activating FactorThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Diethylstilbestrol.Approved, Nutraceutical
PravastatinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Prazosin.Approved
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Diethylstilbestrol.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Diethylstilbestrol.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Diethylstilbestrol.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Diethylstilbestrol.Experimental
PrimidoneThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Prinomastat.Investigational
ProbenecidThe serum concentration of Diethylstilbestrol can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Diethylstilbestrol can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Diethylstilbestrol can be increased when it is combined with Propranolol.Approved, Investigational
Protein CDiethylstilbestrol may decrease the anticoagulant activities of Protein C.Approved
Protein S humanDiethylstilbestrol may decrease the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeDiethylstilbestrol may decrease the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Prucalopride.Approved
QuercetinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Quinacrine.Approved
QuinaprilThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Quinine.Approved
RacecadotrilThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Racecadotril.Investigational
RamiprilThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Ramipril.Approved
RanitidineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Regorafenib.Approved
RemikirenThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Remikiren.Approved
ReserpineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Reserpine.Approved
ReviparinDiethylstilbestrol may decrease the anticoagulant activities of Reviparin.Approved
RifabutinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Rilpivirine.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Diethylstilbestrol.Approved
RitonavirThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Rivaroxaban.Approved
RofecoxibRofecoxib may increase the thrombogenic activities of Diethylstilbestrol.Investigational, Withdrawn
RolapitantThe serum concentration of Diethylstilbestrol can be increased when it is combined with Rolapitant.Approved
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
SaquinavirThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Saxagliptin.Approved
ScopolamineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Diethylstilbestrol.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Sertraline.Approved
SimeprevirThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Sitagliptin.Approved, Investigational
Somatropin recombinantThe therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Diethylstilbestrol.Approved, Investigational
SorafenibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Sorafenib.Approved, Investigational
SpiraprilThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Spirapril.Approved
SpironolactoneThe serum concentration of Diethylstilbestrol can be increased when it is combined with Spironolactone.Approved
St. John's WortThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Staurosporine.Experimental
StreptozocinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Diethylstilbestrol can be increased when it is combined with Sulfinpyrazone.Approved
SulodexideDiethylstilbestrol may decrease the anticoagulant activities of Sulodexide.Approved, Investigational
SumatriptanThe serum concentration of Diethylstilbestrol can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Diethylstilbestrol can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Telaprevir.Approved
TelmisartanThe serum concentration of Diethylstilbestrol can be increased when it is combined with Telmisartan.Approved, Investigational
TemocaprilThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Diethylstilbestrol can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Diethylstilbestrol can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone PropionateThe metabolism of Diethylstilbestrol can be decreased when combined with Testosterone Propionate.Approved, Vet Approved
ThalidomideDiethylstilbestrol may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Diethylstilbestrol.Approved
ThiamylalThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Thiamylal.Approved, Vet Approved
ThiopentalThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Thiopental.Approved, Vet Approved
ThiorphanThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Thiorphan.Experimental
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Diethylstilbestrol.Approved
TicagrelorThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ticagrelor.Approved
TipranavirDiethylstilbestrol may increase the dermatologic adverse activities of Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Diethylstilbestrol.Approved
TolcaponeThe metabolism of Diethylstilbestrol can be decreased when combined with Tolcapone.Approved, Withdrawn
TolvaptanThe serum concentration of Diethylstilbestrol can be increased when it is combined with Tolvaptan.Approved
TopiramateThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
TrandolaprilThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Trandolapril.Approved
Tranexamic AcidDiethylstilbestrol may increase the thrombogenic activities of Tranexamic Acid.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Diethylstilbestrol.Approved, Investigational
TrazodoneThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Trazodone.Approved, Investigational
TretinoinThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Diethylstilbestrol.Approved, Vet Approved
TrifluoperazineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Troleandomycin.Approved
UbenimexThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Ubenimex.Experimental
UlinastatinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Ulinastatin.Investigational
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Diethylstilbestrol.Approved, Investigational
ValdecoxibValdecoxib may increase the thrombogenic activities of Diethylstilbestrol.Investigational, Withdrawn
VenlafaxineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Verapamil.Approved
VildagliptinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Vinorelbine.Approved, Investigational
Vitamin CThe serum concentration of Diethylstilbestrol can be increased when it is combined with Vitamin C.Approved, Nutraceutical
VoriconazoleThe metabolism of Diethylstilbestrol can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinDiethylstilbestrol may decrease the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
Ym150The serum concentration of Diethylstilbestrol can be decreased when it is combined with Ym150.Investigational
ZimelidineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Zimelidine.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Adler, E.,Gie, G.J. and von Euler, H.; US. Patent 2,421,401; June 3, 1947; assigned to Hoffmann-La Roche, Inc.

General References
  1. Authors unspecified: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med. 1984 Nov 15;311(20):1281-6. [PubMed:6436700 ]
  2. DIECKMANN WJ, DAVIS ME, RYNKIEWICZ LM, POTTINGER RE: Does the administration of diethylstilbestrol during pregnancy have therapeutic value? Am J Obstet Gynecol. 1953 Nov;66(5):1062-81. [PubMed:13104505 ]
  3. Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S: Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981 Jan 1;304(1):16-21. [PubMed:7001242 ]
  4. Kuchera LK: Postcoital contraception with diethylstilbestrol. JAMA. 1971 Oct 25;218(4):562-3. [PubMed:5171004 ]
  5. Herbst AL, Ulfelder H, Poskanzer DC: Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971 Apr 15;284(15):878-81. [PubMed:5549830 ]
External Links
ATC CodesL02AA01G03CC05L02AA04G03CB02
AHFS Codes
  • 68:16.04
PDB Entries
FDA labelNot Available
MSDSDownload (73.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9973
Blood Brain Barrier-0.5559
Caco-2 permeable+0.8264
P-glycoprotein substrateSubstrate0.5737
P-glycoprotein inhibitor INon-inhibitor0.6542
P-glycoprotein inhibitor IINon-inhibitor0.8478
Renal organic cation transporterNon-inhibitor0.8465
CYP450 2C9 substrateNon-substrate0.8149
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5107
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.9064
CYP450 2D6 inhibitorNon-inhibitor0.7017
CYP450 2C19 inhibitorInhibitor0.9198
CYP450 3A4 inhibitorInhibitor0.8361
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9488
Ames testNon AMES toxic0.9579
CarcinogenicityNon-carcinogens0.6772
BiodegradationNot ready biodegradable0.9111
Rat acute toxicity1.9462 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6894
hERG inhibition (predictor II)Non-inhibitor0.6408
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Bristol myers squibb
  • Eli lilly and co
  • Tablicaps inc
  • Bayer pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
LiquidIntravenous250 mg
TabletOral100 mg
TabletOral1 mg
TabletOral0.105 mg
TabletOral0.51 mg
TabletOral1.0 mg
TabletOral.1 mg
TabletOral.5 mg
Prices
Unit descriptionCostUnit
Diethylstilbestrol powder13.77USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point172Adler, E.,Gie, G.J. and von Euler, H.; US. Patent 2,421,401; June 3, 1947; assigned to Hoffmann-La Roche, Inc.
water solubility12 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP5.07HANSCH,C ET AL. (1995)
logS-4.35ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0109 mg/mLALOGPS
logP4.62ALOGPS
logP5.19ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)9.13ChemAxon
pKa (Strongest Basic)-6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area40.46 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity83.24 m3·mol-1ChemAxon
Polarizability30.69 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.87 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassStilbenes
Sub ClassNot Available
Direct ParentStilbenes
Alternative Parents
Substituents
  • Stilbene
  • Phenylpropene
  • Phenylpropane
  • Phenol
  • Benzenoid
  • Monocyclic benzene moiety
  • Hydrocarbon derivative
  • Organooxygen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription fact...
Gene Name:
ESR1
Uniprot ID:
P03372
Molecular Weight:
66215.45 Da
References
  1. Munoz G, Ovilo C, Estelle J, Silio L, Fernandez A, Rodriguez C: Association with litter size of new polymorphisms on ESR1 and ESR2 genes in a Chinese-European pig line. Genet Sel Evol. 2007 Mar-Apr;39(2):195-206. Epub 2007 Feb 17. [PubMed:17306201 ]
  2. Dixon A, Wells CC, Singh S, Babayan R, Maric C: Renoprotective effects of a selective estrogen receptor modulator, raloxifene, in an animal model of diabetic nephropathy. Am J Nephrol. 2007;27(2):120-8. Epub 2007 Feb 15. [PubMed:17308373 ]
  3. Hart SA, Snyder MA, Smejkalova T, Woolley CS: Estrogen mobilizes a subset of estrogen receptor-alpha-immunoreactive vesicles in inhibitory presynaptic boutons in hippocampal CA1. J Neurosci. 2007 Feb 21;27(8):2102-11. [PubMed:17314305 ]
  4. Baron S, Escande A, Alberola G, Bystricky K, Balaguer P, Richard-Foy H: Estrogen receptor alpha and the activating protein-1 complex cooperate during insulin-like growth factor-I-induced transcriptional activation of the pS2/TFF1 gene. J Biol Chem. 2007 Apr 20;282(16):11732-41. Epub 2007 Feb 22. [PubMed:17317669 ]
  5. Bains M, Cousins JC, Roberts JL: Neuroprotection by estrogen against MPP+-induced dopamine neuron death is mediated by ERalpha in primary cultures of mouse mesencephalon. Exp Neurol. 2007 Apr;204(2):767-76. Epub 2007 Jan 25. [PubMed:17320868 ]
  6. Kwok KC, Cheung NH: Measuring binding kinetics of ligands with tethered receptors by fluorescence polarization and total internal reflection fluorescence. Anal Chem. 2010 May 1;82(9):3819-25. doi: 10.1021/ac1002245. [PubMed:20387803 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Orphan receptor that acts as transcription activator in the absence of bound ligand. Binds specifically to an estrogen response element and activates reporter genes controlled by estrogen response elements (By similarity). Induces the expression of PERM1 in the skeletal muscle.
Gene Name:
ESRRG
Uniprot ID:
P62508
Molecular Weight:
51305.485 Da
References
  1. Greschik H, Flaig R, Renaud JP, Moras D: Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity. J Biol Chem. 2004 Aug 6;279(32):33639-46. Epub 2004 May 24. [PubMed:15161930 ]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner (PubMed:20074560). Isoform beta-cx lacks ligand binding ability and has no or only very low ere binding activity resulting in the loss of ligand-dependent transactivation ability. DNA-binding by...
Gene Name:
ESR2
Uniprot ID:
Q92731
Molecular Weight:
59215.765 Da
References
  1. Authors unspecified: Final amended report on the safety assessment of Methylparaben, Ethylparaben, Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben, and Benzylparaben as used in cosmetic products. Int J Toxicol. 2008;27 Suppl 4:1-82. doi: 10.1080/10915810802548359. [PubMed:19101832 ]
  2. Geistlinger TR, McReynolds AC, Guy RK: Ligand-selective inhibition of the interaction of steroid receptor coactivators and estrogen receptor isoforms. Chem Biol. 2004 Feb;11(2):273-81. [PubMed:15123288 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
O-methyltransferase activity
Specific Function:
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol.
Gene Name:
COMT
Uniprot ID:
P21964
Molecular Weight:
30036.77 Da
References
  1. Engel LL, Weidenfield J, Merriam GR: Metabolism of diethylstilbestrol by rat liver: a preliminary report. J Toxicol Environ Health Suppl. 1976;1:37-44. [PubMed:11352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name:
CYP19A1
Uniprot ID:
P11511
Molecular Weight:
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Qu YQ, Fang ZZ, Yang L, Gao ZM, Liang R, Zhu LL, Dong PP, Zhang YY, Ge GB, Wang LM: Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol. Pharmazie. 2011 Mar;66(3):216-21. [PubMed:21553654 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Qu YQ, Fang ZZ, Yang L, Gao ZM, Liang R, Zhu LL, Dong PP, Zhang YY, Ge GB, Wang LM: Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol. Pharmazie. 2011 Mar;66(3):216-21. [PubMed:21553654 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Qu YQ, Fang ZZ, Yang L, Gao ZM, Liang R, Zhu LL, Dong PP, Zhang YY, Ge GB, Wang LM: Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol. Pharmazie. 2011 Mar;66(3):216-21. [PubMed:21553654 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Qu YQ, Fang ZZ, Yang L, Gao ZM, Liang R, Zhu LL, Dong PP, Zhang YY, Ge GB, Wang LM: Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol. Pharmazie. 2011 Mar;66(3):216-21. [PubMed:21553654 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Qu YQ, Fang ZZ, Yang L, Gao ZM, Liang R, Zhu LL, Dong PP, Zhang YY, Ge GB, Wang LM: Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol. Pharmazie. 2011 Mar;66(3):216-21. [PubMed:21553654 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Identical protein binding
Specific Function:
Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain.
Gene Name:
TTR
Uniprot ID:
P02766
Molecular Weight:
15886.88 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Sugimoto Y, Tsukahara S, Imai Y, Sugimoto Y, Ueda K, Tsuruo T: Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther. 2003 Jan;2(1):105-12. [PubMed:12533678 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Rao US, Fine RL, Scarborough GA: Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92. [PubMed:7914405 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on November 04, 2016 15:33